Reborna Biosciences, Inc. (Headquarters: Fujisawa City, Kanagawa Prefecture; Representative Director: Koji Fuji; hereinafter, “Reborna”) and Kissei Pharmaceutical Co., Ltd. (Headquarters: Matsumoto City, Nagano Prefecture; Representative Director, Chairman and CEO: Mutsuo Kanzawa; hereinafter, “Kissei Pharmaceutical”) signed a research collaboration agreement on drug discovery in the field of rare diseases on September 9, 2024.

Under this agreement, Reborna will provide its drug discovery platform specializing in the drug discovery of RNA-targeting small molecule drugs and will collaborate the drug discovery research for genetic rare diseases selected by both companies. Kissei Pharmaceutical will pay Reborna an upfront fee, research expenses, as well as research, development and sales milestone payments and royalties based on sales. Kissei will retain the rights to develop and commercialize worldwide the development candidate compounds discovered through the research collaboration.

Under the agreement, Reborna and Kissei will combine their research and development capabilities to promote research and development of drugs for rare genetic diseases.

■Comment from Kissei Pharmaceutical Co., Ltd. Chairman and CEO: Mutsuo Kanzawa
As a drug discovery and research and development company, we are actively engaged in open innovation to realize innovative small molecule drug discovery. Through this research collaboration, we aim to accelerate the research and development of original pharmaceuticals by combining Reborna’s innovative drug discovery platform with our small molecule drug discovery capabilities, and to create drugs for intractable rare diseases.

■Comment from Reborna Biosciences Inc. Representative Director: Koji Fuji
We are very excited for this research collaboration that fully leverages our drug discovery platform and Kissei Pharmaceutical’s robust research and development capabilities. Through open innovation with Kissei Pharmaceutical, we will continue to challenge ourselves to acquire groundbreaking insights and develop original new drugs to address key challenges in drug discovery research for rare disease.

About Kissei Pharmaceutical Co., Ltd.
Kissei Pharmaceutical Co., Ltd. is a drug discovery and research company that is committed to providing innovative new medicines to patients around the world under the management philosophy of “contributing to society through high-quality pharmaceuticals” and “serving society through our members.” We are working to expand our product portfolio in the fields of urology, nephrology and dialysis, as well as areas with high unmet medical needs.
For more information about Kissei Pharmaceutical Co., Ltd., please visit https://www.kissei.co.jp/.

About Reborna Biosciences, Inc.
Reborna is engaged in drug discovery research for oral drugs that show disease modifying effects through normalizing RNA function by using small molecule drugs with high affinity for RNA. By making RNA that governs protein synthesis, the drug discovery target, we will provide drugs that offer a new approach to diseases that have proved difficult to treat until now.　We will contribute to society by providing new drugs that enable patients suffering from rare genetic diseases and their families to feel that they have been reborn.
For more information, please visit http://rebornabiosciences.com.